Geraldine Ferron‐Brady

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French et al. · JNCI Cancer Spectrum · 2019 · 207 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia

Walter Gubelin Harcha, Julia Barboza Martínez, Tsen‐Fang Tsai et al. · Journal of the American Academy of Dermatology · 2014 · 169 citations

Medicine, Endocrinology, Pharmacotherapy +17

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos et al. · Cancer Chemotherapy and Pharmacology · 2014 · 158 citations

Medicine, Oncology, Pharmacology +15

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

Todd M. Bauer, Benjamin Besse, Alex Martínez‐Martí et al. · Journal of Thoracic Oncology · 2019 · 78 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes

Kimberly N. Smitheman, Tesa Severson, Satyajit Rajapurkar et al. · Haematologica · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacology +16